About which medication would the nurse teach the patient who is prescribed an antiperistaltic agent

1. Bartlett J.G., Chang T.W., Gurwith M., Gorbach S.L., Onderdonk A.B. Antibiotic-associated pseudomembranous colitis due to toxin-producing Clostridia. N Engl J Med. 1978;298(10):531–534. [PubMed] [Google Scholar]

2. Khanna S., Pardi D.S. The growing incidence and severity of Clostridium difficile infection in inpatient and outpatient settings. Expert Rev Gastroenterol Hepatol. 2010;4(4):409–416. [PubMed] [Google Scholar]

3. Loo V.G., Poirier L., Miller M.A. A predominantly clonal multi-institutional outbreak of Clostridium difficile-associated diarrhea with high morbidity and mortality [published correction appears in N Engl J Med. 2006;354(20):2200] N Engl J Med. 2005;353(23):2442–2449. [PubMed] [Google Scholar]

4. Khanna S., Pardi D.S., Aronson S.L. The epidemiology of community-acquired Clostridium difficile infection: a population-based study [published correction appears in Am J Gastroenterol. 2012;107(1):150] Am J Gastroenterol. 2011;107(1):89–95. [PMC free article] [PubMed] [Google Scholar]

5. Muto C.A., Pokrywka M., Shutt K. A large outbreak of Clostridium difficile-associated disease with an unexpected proportion of deaths and colectomies at a teaching hospital following increased fluoroquinolone use. Infect Control Hosp Epidemiol. 2005;26(3):273–280. [PubMed] [Google Scholar]

6. Pépin J., Valiquette L., Alary M.E. Clostridium difficile-associated diarrhea in a region of Quebec from 1991 to 2003: a changing pattern of disease severity. CMAJ. 2004;171(5):466–472. [PMC free article] [PubMed] [Google Scholar]

7. Kelly C.P., LaMont J.T. Clostridium difficile: more difficult than ever [published correction appears in N Engl J Med. 2010;363(16):1585] N Engl J Med. 2008;359(18):1932–1940. [PubMed] [Google Scholar]

8. Ricciardi R., Rothenberger D.A., Madoff R.D., Baxter N.N. Increasing prevalence and severity of Clostridium difficile colitis in hospitalized patients in the United States. Arch Surg. 2007;142(7):624–631. discussion 631. [PubMed] [Google Scholar]

9. Zilberberg M.D., Shorr A.F., Kollef M.H. Increase in Clostridium difficile-related hospitalizations among infants in the United States, 2000-2005. Pediatr Infect Dis J. 2008;27(12):1111–1113. [PubMed] [Google Scholar]

10. Zilberberg M.D., Shorr A.F., Kollef M.H. Increase in adult Clostridium difficile-related hospitalizations and case-fatality rate, United States, 2000-2005. Emerg Infect Dis. 2008;14(6):929–931. [PMC free article] [PubMed] [Google Scholar]

11. McDonald L.C., Owings M., Jernigan D.B. Clostridium difficile infection in patients discharged from US short-stay hospitals, 1996-2003. Emerg Infect Dis. 2006;12(3):409–415. [PMC free article] [PubMed] [Google Scholar]

12. McDonald L.C., Coignard B., Dubberke E., Ad Hoc Clostridium difficile Surveillance Working Group Recommendations for surveillance of Clostridium difficile-associated disease. Infect Control Hosp Epidemiol. 2007;28(2):140–145. [PubMed] [Google Scholar]

13. Cohen S.H., Gerding D.N., Johnson S., Society for Healthcare Epidemiology of America; Infectious Diseases Society of America Clinical practice guidelines for Clostridium difficile infection in adults: 2010 update by the Society for Healthcare Epidemiology of America (SHEA) and the Infectious Diseases Society of America (IDSA) Infect Control Hosp Epidemiol. 2010;31(5):431–455. [PubMed] [Google Scholar]

14. Khanna S., Pardi D.S., Aronson S.L., Kammer P.P., Baddour L.M. Outcomes in community-acquired Clostridium difficile infection. Aliment Pharmacol Ther. 2012;35(5):613–618. [PMC free article] [PubMed] [Google Scholar]

15. Kim J., Smathers S.A., Prasad P., Leckerman K.H., Coffin S., Zaoutis T. Epidemiological features of Clostridium difficile-associated disease among inpatients at children's hospitals in the United States, 2001-2006. Pediatrics. 2008;122(6):1266–1270. [PubMed] [Google Scholar]

16. Benson L., Song X., Campos J., Singh N. Changing epidemiology of Clostridium difficile-associated disease in children. Infect Control Hosp Epidemiol. 2007;28(11):1233–1235. [PubMed] [Google Scholar]

17. Enoch D.A., Butler M.J., Pai S., Aliyu S.H., Karas J.A. Clostridium difficile in children: colonisation and disease. J Infect. 2011;63(2):105–113. [PubMed] [Google Scholar]

18. Langley J.M., LeBlanc J.C., Hanakowski M., Goloubeva O. The role of Clostridium difficile and viruses as causes of nosocomial diarrhea in children. Infect Control Hosp Epidemiol. 2002;23(11):660–664. [PubMed] [Google Scholar]

19. Klein E.J., Boster D.R., Stapp J.R. Diarrhea etiology in a children's hospital emergency department: a prospective cohort study. Clin Infect Dis. 2006;43(7):807–813. [PubMed] [Google Scholar]

20. Boenning D.A., Fleisher G.R., Campos J.M., Hulkower C.W., Quinlan R.W. Clostridium difficile in a pediatric outpatient population. Pediatr Infect Dis. 1982;1(5):336–338. [PubMed] [Google Scholar]

21. Otten A.M., Reid-Smith R.J., Fazil A., Weese J.S. Disease transmission model for community-associated Clostridium difficile infection. Epidemiol Infect. 2010;138(6):907–914. [PubMed] [Google Scholar]

22. Viscidi R., Willey S., Bartlett J.G. Isolation rates and toxigenic potential of Clostridium difficile isolates from various patient populations. Gastroenterology. 1981;81(1):5–9. [PubMed] [Google Scholar]

23. MacCannell D.R., Louie T.J., Gregson D.B. Molecular analysis of Clostridium difficile PCR ribotype 027 isolates from Eastern and Western Canada. J Clin Microbiol. 2006;44(6):2147–2152. [PMC free article] [PubMed] [Google Scholar]

24. Merrigan M., Venugopal A., Mallozzi M. Human hypervirulent Clostridium difficile strains exhibit increased sporulation as well as robust toxin production. J Bacteriol. 2010;192(19):4904–4911. [PMC free article] [PubMed] [Google Scholar]

25. Kuijper E.J., Barbut F., Brazier J.S. Update of Clostridium difficile infection due to PCR ribotype 027 in Europe, 2008. Euro Surveill. 2008;13(31) pii:18942. [PubMed] [Google Scholar]

26. Kuijper E.J., Coignard B., Brazier J.S. Update of Clostridium difficile-associated disease due to PCR ribotype 027 in Europe. Euro Surveill. 2007;12(6):E1–E2. [PubMed] [Google Scholar]

27. Miller M., Gravel D., Mulvey M. Health care-associated Clostridium difficile infection in Canada: patient age and infecting strain type are highly predictive of severe outcome and mortality. Clin Infect Dis. 2010;50(2):194–201. [PubMed] [Google Scholar]

28. Hubert B., Loo V.G., Bourgault A.M. A portrait of the geographic dissemination of the Clostridium difficile North American pulsed-field type 1 strain and the epidemiology of C. difficile-associated disease in Quebec. Clin Infect Dis. 2007;44(2):238–244. [PubMed] [Google Scholar]

29. Goorhuis A., Van der Kooi T., Vaessen N. Spread and epidemiology of Clostridium difficile polymerase chain reaction ribotype 027/toxinotype III in The Netherlands. Clin Infect Dis. 2007;45(6):695–703. [PubMed] [Google Scholar]

30. Morgan O.W., Rodrigues B., Elston T. Clinical severity of Clostridium difficile PCR ribotype 027: a case-case study. PLoS One. 2008;3(3):e1812. [PMC free article] [PubMed] [Google Scholar]

31. Thibault A., Miller M.A., Gaese C. Risk factors for the development of Clostridium difficile-associated diarrhea during a hospital outbreak. Infect Control Hosp Epidemiol. 1991;12(6):345–348. [PubMed] [Google Scholar]

32. Shah K., Pass L.A., Cox M., Lanham M., Arnold F.W. Evaluating contemporary antibiotics as a risk factor for Clostridium difficile infection in surgical trauma patients. J Trauma Acute Care Surg. 2012;72(3):691–695. [PubMed] [Google Scholar]

33. Rousseau C., Levenez F., Fouqueray C., Doré J., Collignon A., Lepage P. Clostridium difficile colonization in early infancy is accompanied by changes in intestinal microbiota composition. J Clin Microbiol. 2011;49(3):858–865. [PMC free article] [PubMed] [Google Scholar]

34. Rea M.C., O'Sullivan O., Shanahan F. Clostridium difficile carriage in elderly subjects and associated changes in the intestinal microbiota. J Clin Microbiol. 2012;50(3):867–875. [PMC free article] [PubMed] [Google Scholar]

35. Manges A.R., Labbe A., Loo V.G. Comparative metagenomic study of alterations to the intestinal microbiota and risk of nosocomial Clostridum difficile-associated disease. J Infect Dis. 2010;202(12):1877–1884. [PubMed] [Google Scholar]

36. Dethlefsen L., Relman D.A. Incomplete recovery and individualized responses of the human distal gut microbiota to repeated antibiotic perturbation. Proc Natl Acad Sci U S A. 2011;108(suppl 1):4554–4561. [PMC free article] [PubMed] [Google Scholar]

37. Mullane K.M., Miller M.A., Weiss K. Efficacy of fidaxomicin versus vancomycin as therapy for Clostridium difficile infection in individuals taking concomitant antibiotics for other concurrent infections [published correction appears in Clin Infect Dis. 2011;53(12):1312. Dosage error in article text] Clin Infect Dis. 2011;53(5):440–447. [PMC free article] [PubMed] [Google Scholar]

38. Dubberke E.R., Reske K.A., Noble-Wang J. Prevalence of Clostridium difficile environmental contamination and strain variability in multiple health care facilities. Am J Infect Control. 2007;35(5):315–318. [PubMed] [Google Scholar]

39. Kim K.H., Fekety R., Batts D.H. Isolation of Clostridium difficile from the environment and contacts of patients with antibiotic-associated colitis. J Infect Dis. 1981;143(1):42–50. [PubMed] [Google Scholar]

40. Dubberke E.R., Gerding D.N., Classen D. Strategies to prevent Clostridium difficile infections in acute care hospitals. Infect Control Hosp Epidemiol. 2008;29(suppl 1):S81–S92. [PubMed] [Google Scholar]

41. Khanna S., Pardi D.S. IBD: Poor outcomes after Clostridium difficile infection in IBD. Nat Rev Gastroenterol Hepatol. 2012;9(6):307–308. [PubMed] [Google Scholar]

42. Ananthakrishnan A.N., McGinley E.L., Binion D.G. Excess hospitalisation burden associated with Clostridium difficile in patients with inflammatory bowel disease. Gut. 2008;57(2):205–210. [PubMed] [Google Scholar]

43. Patriarchi F., Rolla M., Maccioni F. Clostridium difficile-related pancolitis in lung-transplanted patients with cystic fibrosis. Clin Transplant. 2011;25(1):E46–E51. [PubMed] [Google Scholar]

44. Kyne L., Sougioultzis S., McFarland L.V., Kelly C.P. Underlying disease severity as a major risk factor for nosocomial Clostridium difficile diarrhea. Infect Control Hosp Epidemiol. 2002;23(11):653–659. [PubMed] [Google Scholar]

45. Linsky A., Gupta K., Lawler E.V., Fonda J.R., Hermos J.A. Proton pump inhibitors and risk for recurrent Clostridium difficile infection [published correction appears in Arch Intern Med 2010;170(13):1100] Arch Intern Med. 2010;170(9):772–778. [PubMed] [Google Scholar]

46. Lowe D.O., Mamdani M.M., Kopp A., Low D.E., Juurlink D.N. Proton pump inhibitors and hospitalization for Clostridium difficile-associated disease: a population-based study. Clin Infect Dis. 2006;43(10):1272–1276. [PubMed] [Google Scholar]

47. Dial S., Delaney J.A., Schneider V., Suissa S. Proton pump inhibitor use and risk of community-acquired Clostridium difficile-associated disease defined by prescription for oral vancomycin therapy. CMAJ. 2006;175(7):745–748. [PMC free article] [PubMed] [Google Scholar]

48. Dial S., Delaney J.A., Barkun A.N., Suissa S. Use of gastric acid-suppressive agents and the risk of community-acquired Clostridium difficile-associated disease. JAMA. 2005;294(23):2989–2995. [PubMed] [Google Scholar]

49. Rao A., Jump R.L., Pultz N.J., Pultz M.J., Donskey C.J. In vitro killing of nosocomial pathogens by acid and acidified nitrite. Antimicrob Agents Chemother. 2006;50(11):3901–3904. [PMC free article] [PubMed] [Google Scholar]

50. Wilson K.H., Sheagren J.N., Freter R. Population dynamics of ingested Clostridium difficile in the gastrointestinal tract of the Syrian hamster. J Infect Dis. 1985;151(2):355–361. [PubMed] [Google Scholar]

51. Pépin J., Saheb N., Coulombe M.A. Emergence of fluoroquinolones as the predominant risk factor for Clostridium difficile-associated diarrhea: a cohort study during an epidemic in Quebec. Clin Infect Dis. 2005;41(9):1254–1260. [PubMed] [Google Scholar]

52. Khanna S., Aronson S.L., Kammer P.P., Baddour L.M., Pardi D.S. Gastric acid suppression and outcomes in Clostridium difficile infection: a population-based study. Mayo Clin Proc. 2012;87(7):636–642. [PMC free article] [PubMed] [Google Scholar]

53. Khanna S., Pardi D.S. Gastric acid suppression and Clostridium difficile infection: is there a causal connection [letter]? Clin Gastroenterol Hepatol. 2012;10(5):564. author reply 564. [PubMed] [Google Scholar]

54. Kufelnicka A.M., Kirn T.J. Effective utilization of evolving methods for the laboratory diagnosis of Clostridium difficile infection. Clin Infect Dis. 2011;52(12):1451–1457. [PubMed] [Google Scholar]

55. Carroll K.C. Tests for the diagnosis of Clostridium difficile infection: the next generation. Anaerobe. 2011;17(4):170–174. [PubMed] [Google Scholar]

56. Khanna S., Pardi D.S., Rosenblatt J.E., Patel R., Kammer P.P., Baddour L.M. An evaluation of repeat stool testing for Clostridium difficile infection by polymerase chain reaction . J Clin Gastroenterol. 2012 [published online ahead of print] [PubMed] [Google Scholar]

57. Sloan L.M., Duresko B.J., Gustafson D.R., Rosenblatt J.E. Comparison of real-time PCR for detection of the tcdC gene with four toxin immunoassays and culture in diagnosis of Clostridium difficile infection. J Clin Microbiol. 2008;46(6):1996–2001. [PMC free article] [PubMed] [Google Scholar]

58. Peterson L.R., Mehta M.S., Patel P.A. Laboratory testing for Clostridium difficile infection: light at the end of the tunnel. Am J Clin Pathol. 2011;136(3):372–380. [PubMed] [Google Scholar]

59. Fujitani S., George W.L., Murthy A.R. Comparison of clinical severity score indices for Clostridium difficile infection. Infect Control Hosp Epidemiol. 2011;32(3):220–228. [PubMed] [Google Scholar]

60. Lungulescu O.A., Cao W., Gatskevich E., Tlhabano L., Stratidis J.G. CSI: a severity index for Clostridium difficile infection at the time of admission. J Hosp Infect. 2011;79(2):151–154. [PubMed] [Google Scholar]

61. Zar F.A., Bakkanagari S.R., Moorthi K.M., Davis M.B. A comparison of vancomycin and metronidazole for the treatment of Clostridium difficile-associated diarrhea, stratified by disease severity. Clin Infect Dis. 2007;45(3):302–307. [PubMed] [Google Scholar]

62. Belmares J., Gerding D.N., Parada J.P., Miskevics S., Weaver F., Johnson S. Outcome of metronidazole therapy for Clostridium difficile disease and correlation with a scoring system. J Infect. 2007;55(6):495–501. [PubMed] [Google Scholar]

63. Keddis M.T., Khanna S., Noheria A., Badour L.M., Pardi D.S., Qian Q. Clostridium difficile infection in patients with chronic kidney disease. Mayo Clin Proc. 2012 [In Press] [PMC free article] [PubMed] [Google Scholar]

64. Shivashankar R., Khanna S., Kammer P.P. Clinical predictors of severe complicated Clostridium difficile infection. Am J Gastroenterol. 2011;106(S2):S162. [Google Scholar]

65. Orenstein R., Aronhalt K.C., McManus J.E., Jr, Fedraw L.A. A targeted strategy to wipe out Clostridium difficile. Infect Control Hosp Epidemiol. 2011;32(11):1137–1139. [PubMed] [Google Scholar]

66. Pepin J., Alary M.E., Valiquette L. Increasing risk of relapse after treatment of Clostridium difficile colitis in Quebec, Canada. Clin Infect Dis. 2005;40(11):1591–1597. [PubMed] [Google Scholar]

67. Musher D.M., Aslam S., Logan N. Relatively poor outcome after treatment of Clostridium difficile colitis with metronidazole. Clin Infect Dis. 2005;40(11):1586–1590. [PubMed] [Google Scholar]

68. Gerber M., Ackermann G. OPT-80, a macrocyclic antimicrobial agent for the treatment of Clostridium difficile infections: a review. Exp Opin Investig Drugs. 2008;17(4):547–553. [PubMed] [Google Scholar]

69. Finegold S.M., Molitoris D., Vaisanen M.L., Song Y., Liu C., Bolaños M. In vitro activities of OPT-80 and comparator drugs against intestinal bacteria. Antimicrob Agents Chemother. 2004;48(12):4898–4902. [PMC free article] [PubMed] [Google Scholar]

70. Ackermann G., Löffler B., Adler D., Rodloff A.C. In vitro activity of OPT-80 against Clostridium difficile. Antimicrob Agents Chemother. 2004;48(6):2280–2282. [PMC free article] [PubMed] [Google Scholar]

71. Karlowsky J.A., Laing N.M., Zhanel G.G. In vitro activity of OPT-80 tested against clinical isolates of toxin-producing Clostridium difficile. Antimicrob Agents Chemother. 2008;52(11):4163–4165. [PMC free article] [PubMed] [Google Scholar]

72. Louie T.J., Miller M.A., Mullane K.M., OPT-80-003 Clinical Study Group Fidaxomicin versus vancomycin for Clostridium difficile infection. N Engl J Med. 2011;364(5):422–431. [PubMed] [Google Scholar]

73. Cornely O.A., Crook D.W., Esposito R., OPT-80-004 Clinical Study Group [Collaborators (82)] Fidaxomicin versus vancomycin for infection with Clostridium difficile in Europe, Canada, and the USA: a double-blind, non-inferiority, randomised controlled trial. Lancet Infect Dis. 2012;12(4):281–289. [PubMed] [Google Scholar]

74. Lancaster J.W., Matthews S.J. Fidaxomicin: the newest addition to the armamentarium against Clostridium difficile infections. Clin Ther. 2012;34(1):1–13. [PubMed] [Google Scholar]

75. Hu M.Y., Katchar K., Kyne L. Prospective derivation and validation of a clinical prediction rule for recurrent Clostridium difficile infection. Gastroenterology. 2009;136(4):1206–1214. [PubMed] [Google Scholar]

76. Johnson S. Recurrent Clostridium difficile infection: a review of risk factors, treatments, and outcomes. J Infect. 2009;58(6):403–410. [PubMed] [Google Scholar]

77. Gough E., Shaikh H., Manges A.R. Systematic review of intestinal microbiota transplantation (fecal bacteriotherapy) for recurrent Clostridium difficile infection. Clin Infect Dis. 2011;53(10):994–1002. [PubMed] [Google Scholar]

78. Hamilton M.J., Weingarden A.R., Sadowsky M.J., Khoruts A. Standardized frozen preparation for transplantation of fecal microbiota for recurrent Clostridium difficile infection. Am J Gastroenterol. 2012;107(5):761–767. [PubMed] [Google Scholar]

79. Mattila E., Uusitalo-Seppälä R., Wuorela M. Fecal transplantation, through colonoscopy, is effective therapy for recurrent Clostridium difficile infection. Gastroenterology. 2012;142(3):490–496. [PubMed] [Google Scholar]

80. Kassam Z., Hundal R., Marshall J.K., Lee C.H. Fecal transplant via retention enema for refractory or recurrent Clostridium difficile infection. Arch Intern Med. 2012;172(2):191–193. [PubMed] [Google Scholar]

81. Bakken J.S., Borody T., Brandt L.J., Fecal Microbiota Transplantation Workgroup Treating Clostridium difficile infection with fecal microbiota transplantation. Clin Gastroenterol Hepatol. 2011;9(12):1044–1049. [PMC free article] [PubMed] [Google Scholar]

82. Koo H.L., DuPont H.L. Rifaximin: a unique gastrointestinal-selective antibiotic for enteric diseases. Curr Opin Gastroenterol. 2010;26(1):17–25. [PMC free article] [PubMed] [Google Scholar]

83. DuPont H.L., Jiang Z.D., Okhuysen P.C. A randomized, double-blind, placebo-controlled trial of rifaximin to prevent travelers' diarrhea [published correction appears in Ann Intern Med. 2005;143(3):239] Ann Intern Med. 2005;142(10):805–812. [PubMed] [Google Scholar]

84. Berman A.L. Efficacy of rifaximin and vancomycin combination therapy in a patient with refractory Clostridium difficile-associated diarrhea. J Clin Gastroenterol. 2007;41(10):932–933. [PubMed] [Google Scholar]

85. Johnson S., Schriever C., Galang M., Kelly C.P., Gerding D.N. Interruption of recurrent Clostridium difficile-associated diarrhea episodes by serial therapy with vancomycin and rifaximin. Clin Infect Dis. 2007;44(6):846–848. [PubMed] [Google Scholar]

86. Rubin D.T., Sohi S., Glathar M., Thomas T., Yadron N., Surma B.L. Rifaximin is effective for the treatment of Clostridium difficile-associated diarrhea: results of an open-label pilot study. Gastroenterol Res Pract. 2011;2011:106978. [PMC free article] [PubMed] [Google Scholar]

87. Pardi D.S., Brennan R., Spinnell M. The efficacy and safety of rifaximin vs. vancomycin in the treatment of mild to moderate C. difficile infection: a randomized double-blind active comparator trial. Gastroenterology. 2012;142(5):S-599. [Google Scholar]

88. Garey K.W., Ghantoji S.S., Shah D.N. A randomized, double-blind, placebo-controlled pilot study to assess the ability of rifaximin to prevent recurrent diarrhoea in patients with Clostridium difficile infection. J Antimicrob Chemother. 2011;66(12):2850–2855. [PubMed] [Google Scholar]

89. Musher D.M., Logan N., Bressler A.M., Johnson D.P., Rossignol J.F. Nitazoxanide versus vancomycin in Clostridium difficile infection: a randomized, double-blind study. Clin Infect Dis. 2009;48(4):e41–e46. [PubMed] [Google Scholar]

90. Musher D.M., Logan N., Hamill R.J. Nitazoxamide for the treatment of Clostridium difficile colitis [letter] Clin Infect Dis. 2006;43(4):421–427. [PubMed] [Google Scholar]Young J.D., Mangino E., Stevenson K.B., Koletar S.L. Nitazoxanide versus metronidazole for Clostridium difficile-associated colitis [letter] Clin Infect Dis. 2007;44(1):152. author reply 152-154. [PubMed] [Google Scholar]

91. Taylor N.S., Bartlett J.G. Binding of Clostridium difficile cytotoxin and vancomycin by anion-exchange resins. J Infect Dis. 1980;141(1):92–97. [PubMed] [Google Scholar]

92. Abougergi M.S., Broor A., Cui W., Jaar B.G. Intravenous immunoglobulin for the treatment of severe Clostridium difficile colitis: an observational study and review of the literature. J Hosp Med. 2010;5(1):E1–E9. [PubMed] [Google Scholar]

93. Leav B.A., Blair B., Leney M. Serum anti-toxin B antibody correlates with protection from recurrent Clostridium difficile infection (CDI) Vaccine. 2010;28(4):965–969. [PubMed] [Google Scholar]

94. Abougergi M.S., Kwon J.H. Intravenous immunoglobulin for the treatment of Clostridium difficile infection: a review. Dig Dis Sci. 2011;56(1):19–26. [PubMed] [Google Scholar]

95. Lowy I., Molrine D.C., Leav B.A. Treatment with monoclonal antibodies against Clostridium difficile toxins. N Engl J Med. 2010;362(3):197–205. [PubMed] [Google Scholar]

96. Kotloff K.L., Wasserman S.S., Losonsky G.A. Safety and immunogenicity of increasing doses of a Clostridium difficile toxoid vaccine administered to healthy adults. Infect Immun. 2001;69(2):988–995. [PMC free article] [PubMed] [Google Scholar]

97. Sougioultzis S., Kyne L., Drudy D. Clostridium difficile toxoid vaccine in recurrent C. difficile-associated diarrhea. Gastroenterology. 2005;128(3):764–770. [PubMed] [Google Scholar]

98. Greenberg R.N., Marbury T.C., Foglia G., Warny M. Phase I dose finding studies of an adjuvanted Clostridium difficile toxoid vaccine. Vaccine. 2012;30(13):2245–2249. [PubMed] [Google Scholar]

99. Dendukuri N., Costa V., McGregor M., Brophy J.M. Probiotic therapy for the prevention and treatment of Clostridium difficile-associated diarrhea: a systematic review [published correction appears in CMAJ. 2005;173(4):345] CMAJ. 2005;173(2):167–170. [PMC free article] [PubMed] [Google Scholar]

100. Castagliuolo I., Riegler M.F., Valenick L., LaMont J.T., Pothoulakis C. Saccharomyces boulardii protease inhibits the effects of Clostridium difficile toxins A and B in human colonic mucosa. Infect Immun. 1999;67(1):302–307. [PMC free article] [PubMed] [Google Scholar]

101. Surawicz C.M., McFarland L.V., Elmer G., Chinn J. Treatment of recurrent Clostridium difficile colitis with vancomycin and Saccharomyces boulardii. Am J Gastroenterol. 1989;84(10):1285–1287. [PubMed] [Google Scholar]

102. Surawicz C.M., McFarland L.V., Greenberg R.N. The search for a better treatment for recurrent Clostridium difficile disease: use of high-dose vancomycin combined with Saccharomyces boulardii. Clin Infect Dis. 2000;31(4):1012–1017. [PubMed] [Google Scholar]

103. Longo W.E., Mazuski J.E., Virgo K.S., Lee P., Bahadursingh A.N., Johnson F.E. Outcome after colectomy for Clostridium difficile colitis. Dis Colon Rectum. 2004;47(10):1620–1626. [PubMed] [Google Scholar]

104. Markelov A., Livert D., Kohli H. Predictors of fatal outcome after colectomy for fulminant Clostridium difficile colitis: a 10-year experience. Am Surg. 2011;77(8):977–980. [PubMed] [Google Scholar]

105. Byrn J.C., Maun D.C., Gingold D.S., Baril D.T., Ozao J.J., Divino C.M. Predictors of mortality after colectomy for fulminant Clostridium difficile colitis. Arch Surg. 2008;143(2):150–154. discussion 155. [PubMed] [Google Scholar]

106. Neal M.D., Alverdy J.C., Hall D.E., Simmons R.L., Zuckerbraun B.S. Diverting loop ileostomy and colonic lavage: an alternative to total abdominal colectomy for the treatment of severe, complicated Clostridium difficile associated disease. Ann Surg. 2011;254(3):423–427. discussion 427-429. [PubMed] [Google Scholar]

107. Synnott K., Mealy K., Merry C., Kyne L., Keane C., Quill R. Timing of surgery for fulminating pseudomembranous colitis. Br J Surg. 1998;85(2):229–231. [PubMed] [Google Scholar]

108. Hall J.F., Berger D. Outcome of colectomy for Clostridium difficile colitis: a plea for early surgical management. Am J Surg. 2008;196(3):384–388. [PubMed] [Google Scholar]

109. Ali S.O., Welch J.P., Dring R.J. Early surgical intervention for fulminant pseudomembranous colitis. Am Surg. 2008;74(1):20–26. [PubMed] [Google Scholar]

110. Seder C.W., Villalba M.R., Jr, Robbins J. Early colectomy may be associated with improved survival in fulminant Clostridium difficile colitis: an 8-year experience. Am J Surg. 2009;197(3):302–307. [PubMed] [Google Scholar]